{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:47:18Z","timestamp":1774766838764,"version":"3.50.1"},"reference-count":45,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T00:00:00Z","timestamp":1727481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["FS-2022:0010"],"award-info":[{"award-number":["FS-2022:0010"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","award":["ID21-0086"],"award-info":[{"award-number":["ID21-0086"]}],"id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stiftelsen f\u00f6r Strategisk Forskning","award":["FS-2022:0010"],"award-info":[{"award-number":["FS-2022:0010"]}]},{"name":"Stiftelsen f\u00f6r Strategisk Forskning","award":["ID21-0086"],"award-info":[{"award-number":["ID21-0086"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In a time of climate change, population growth, and globalization, the risk of viral spread has significantly increased. The 21st century has already witnessed outbreaks of Severe Acute Respiratory Syndrome virus (SARS-CoV), Severe Acute Respiratory Syndrome virus 2 (SARS-CoV-2), Ebola virus and Influenza virus, among others. Viruses rapidly adapt and evade human immune systems, complicating the development of effective antiviral countermeasures. Consequently, the need for novel antivirals resilient to viral mutations is urgent. In this study, we developed a CRISPR-Cas13b system to target SARS-CoV-2. Interestingly, this system was also efficient against SARS-CoV, demonstrating broad-spectrum potential. Our findings highlight CRISPR-Cas13b as a promising tool for antiviral therapeutics, underscoring its potential in RNA-virus-associated pandemic responses.<\/jats:p>","DOI":"10.3390\/v16101539","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T04:00:04Z","timestamp":1727668804000},"page":"1539","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A CRISPR-Cas13b System Degrades SARS-CoV and SARS-CoV-2 RNA In Vitro"],"prefix":"10.3390","volume":"16","author":[{"given":"Klara","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8596-4313","authenticated-orcid":false,"given":"Ani","family":"Azatyan","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Ekenberg","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00f6zde","family":"G\u00fc\u00e7l\u00fcler","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sardon Puig","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjo","family":"Puumalainen","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodor","family":"Pramer","sequence":"additional","affiliation":[{"name":"Biomedrex Genetics, Alfred Nobels all\u00e9 8, 14152 Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-5695","authenticated-orcid":false,"given":"Vanessa M.","family":"Monteil","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Public Health Agency of Sweden, 17182 Solna, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mirazimi","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Unit of Clinical Microbiology, Karolinska Institutet, 17177 Stockholm, Sweden"},{"name":"Public Health Agency of Sweden, 17182 Solna, Sweden"},{"name":"National Veterinary Institute, 75189 Uppsala, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ilar\/ilx026","article-title":"Are RNA Viruses Candidate Agents for the Next Global Pandemic? A Review","volume":"58","author":"Vidal","year":"2017","journal-title":"ILAR J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"110969","DOI":"10.1016\/j.celrep.2022.110969","article-title":"Emerging viruses: Cross-species transmission of coronaviruses, filoviruses, henipaviruses, and rotaviruses from bats","volume":"39","author":"Tian","year":"2022","journal-title":"Cell Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"105246","DOI":"10.1016\/j.jcv.2022.105246","article-title":"Human coronaviruses: Origin, host and receptor","volume":"155","author":"Tang","year":"2022","journal-title":"J. Clin. Virol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"McCoullough, L.C., Fareh, M., Hu, W., Sozzi, V., Makhlouf, C., Droungas, Y., Lee, C.L., Takawy, M., Fabb, S.A., and Payne, T.J. (2024). CRISPR-Cas13b-mediated suppression of HBV replication and protein expression. J. Hepatol.","DOI":"10.1016\/j.jhep.2024.05.025"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/s41467-021-24577-9","article-title":"Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance","volume":"12","author":"Fareh","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1038\/s41467-022-30546-7","article-title":"Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro","volume":"13","author":"Zeng","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1002\/mco2.208","article-title":"CRISPR-Cas13d effectively targets SARS-CoV-2 variants, including Delta and Omicron, and inhibits viral infection","volume":"4","author":"Liu","year":"2023","journal-title":"Medcomm"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nguyen, H., Wilson, H., Jayakumar, S., Kulkarni, V., and Kulkarni, S. (2021). Efficient Inhibition of HIV Using CRISPR\/Cas13d Nuclease System. Viruses, 13.","DOI":"10.1101\/2021.07.21.453273"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41587-022-01419-7","article-title":"High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effects","volume":"41","author":"Tong","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR\u2013Cas13","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, Y., Jing, P., Zhou, Y., Zhang, J., Shi, J., Zhang, M., Yang, H., and Fei, J. (2023). The effects of length and sequence of gRNA on Cas13b and Cas13d activity in vitro and in vivo. Biotechnol. J., 18.","DOI":"10.1002\/biot.202300002"},{"key":"ref_12","first-page":"321","article-title":"Chemically modified guide RNAs enhance CRISPR-Cas13 knockdown in human cells","volume":"29","author":"Wessels","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41592-022-01705-x","article-title":"Efficient combinatorial targeting of RNA tran-scripts in single cells with Cas13 RNA Perturb-seq","volume":"20","author":"Wessels","year":"2023","journal-title":"Nat. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kang, B., Zhang, J., Schwoerer, M.P., Nelson, A.N., Schoeman, E., Guo, A., Ploss, A., and Myhrvold, C. (2023). Highly multiplexed mRNA quantitation with CRISPR-Cas13. bioRxiv.","DOI":"10.1101\/2023.08.16.553527"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/s41587-020-0456-9","article-title":"Massively parallel Cas13 screens reveal principles for guide RNA design","volume":"38","author":"Wessels","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2020.04.020","article-title":"Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza","volume":"181","author":"Abbott","year":"2020","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Cui, J., Techakriengkrai, N., Nedumpun, T., and Suradhat, S. (2020). Abrogation of PRRSV infectivity by CRISPR-Cas13b-mediated viral RNA cleavage in mammalian cells. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-66775-3"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1126\/science.aaq0180","article-title":"RNA editing with CRISPR-Cas13","volume":"358","author":"Cox","year":"2017","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/15476286.2019.1669406","article-title":"An overview and metanalysis of machine and deep learning-based CRISPR gRNA design tools","volume":"17","author":"Wang","year":"2019","journal-title":"RNA Biol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bandaru, S., Tsuji, M.H., Shimizu, Y., Usami, K., Lee, S., Takei, N.K., Yoshitome, K., Nishimura, Y., Otsuki, T., and Ito, T. (2020). Structure-based design of gRNA for Cas13. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-68459-4"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105333","DOI":"10.1016\/j.isci.2022.105333","article-title":"Polyvalent guide RNAs for CRISPR antivirals","volume":"25","author":"Bagchi","year":"2022","journal-title":"iScience"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.xcrm.2021.100245","article-title":"A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses","volume":"2","author":"Lin","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100001","DOI":"10.1016\/j.xgen.2021.100001","article-title":"Transcriptome-wide Cas13 guide RNA design for model organisms and viral RNA pathogens","volume":"1","author":"Guo","year":"2021","journal-title":"Cell Genom."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/j.ymthe.2023.03.018","article-title":"Pseudoknot-targeting Cas13b combats SARS-CoV-2 infection by suppressing viral replication","volume":"31","author":"Yu","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/22221751.2020.1719902","article-title":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan","volume":"9","author":"Chan","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Abdelrahman, Z., Li, M., and Wang, X. (2020). Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.552909"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e00168-19","DOI":"10.1128\/CMR.00168-19","article-title":"Host-Directed Antiviral Therapy","volume":"33","author":"Kumar","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Geraghty, R.J., Aliota, M.T., and Bonnac, L.F. (2021). Broad-Spectrum Antiviral Strategies and Nucleoside Analogues. Viruses, 13.","DOI":"10.3390\/v13040667"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6851","DOI":"10.3390\/cimb45080433","article-title":"Recent Advances in Molecular Mechanisms of Nucleoside Antivirals","volume":"45","author":"Kamzeeva","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.molcel.2019.09.013","article-title":"Programmable Inhibition and Detection of RNA Viruses Using Cas13","volume":"76","author":"Freije","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chaves, L.C.S., Orr-Burks, N., Vanover, D., Mosur, V.V., Hosking, S.R., Kumar E. K., P., Jeong, H., Jung, Y., Assump\u00e7\u00e3o, J.A.F., and Peck, H.E. (2024). mRNA-encoded Cas13 treatment of Influenza via site-specific degradation of genomic RNA. PLoS Pathog., 20.","DOI":"10.1371\/journal.ppat.1012345"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41587-021-00822-w","article-title":"Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents","volume":"39","author":"Blanchard","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.cell.2018.02.033","article-title":"Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors","volume":"173","author":"Konermann","year":"2018","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.it.2020.11.003","article-title":"Combining Antivirals and Immunomodulators to Fight COVID-19","volume":"42","author":"Feuillet","year":"2020","journal-title":"Trends Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Hu, W., Kumar, A., Ahmed, S.F., Qi, S., Ma, D.K.G., Chen, H., Singh, G.J., Casan, J.M.L., Haber, M., and Voskoboinik, I. (2024). Single-base tiled screen unveils design principles of PspCas13b for potent and off-target-free RNA silencing. Nat. Struct. Mol. Biol.","DOI":"10.1038\/s41594-024-01336-0"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-022-00884-5","article-title":"Structural biology of SARS-CoV-2: Open the door for novel therapies","volume":"7","author":"Yan","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Islam, J., Islam, N.N., Alom, S., Kabir, M., and Halim, M.A. (2022). A review on structural, non-structural, and accessory proteins of SARS-CoV-2: Highlighting drug target sites. Immunobiology, 228.","DOI":"10.1016\/j.imbio.2022.152302"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1021\/acs.jmedchem.0c01140","article-title":"Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities","volume":"65","author":"Cannalire","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds","volume":"115","author":"John","year":"2015","journal-title":"Antiviral. Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ibrahim, T.M., Ismail, M.I., Bauer, M.R., Bekhit, A.A., and Boeckler, F.M. (2020). Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery: In silico Methods and Benchmarking. Front. Chem., 8.","DOI":"10.3389\/fchem.2020.592289"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Tam, D., Lorenzo-Leal, A.C., Hern\u00e1ndez, L.R., and Bach, H. (2023). Targeting SARS-CoV-2 Non-Structural Proteins. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241613002"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e29396","DOI":"10.1002\/jmv.29396","article-title":"SARS-CoV-2 NSP12 utilizes various host splicing factors for replication and splicing regulation","volume":"96","author":"Yang","year":"2024","journal-title":"J. Med Virol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Aljuaid, A., Salam, A., Almehmadi, M., Baammi, S., Alshabrmi, F.M., Allahyani, M., Al-Zaydi, K.M., Izmirly, A.M., Almaghrabi, S., and Baothman, B.K. (2022). Structural Homology-Based Drug Repurposing Approach for Targeting NSP12 SARS-CoV-2. Molecules, 27.","DOI":"10.3390\/molecules27227732"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e944204","DOI":"10.12659\/MSM.944204","article-title":"Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent \u03b2-Thalassemia","volume":"30","author":"Parums","year":"2024","journal-title":"Med Sci. Monit."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/d41587-023-00016-6","article-title":"The world\u2019s first CRISPR therapy is approved: Who will receive it?","volume":"42","author":"Sheridan","year":"2023","journal-title":"Nat. Biotechnol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1539\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:06:16Z","timestamp":1760112376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/16\/10\/1539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,28]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["v16101539"],"URL":"https:\/\/doi.org\/10.3390\/v16101539","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,28]]}}}